Onglyza (saxagliptin) is prescribed to treat Type 2 diabetes and has been linked to an increased risk of heart failure and pancreatic cancer. In 2014, the New England Journal of Medicine published a study of 16,500 Onglyza users; 27 percent were more likely to be hospitalized for heart failure than those who did not take the drug. In 2013, the Food and Drug Administration warned that people taking Onglyza and similar drugs may be more likely to develop pancreatic cancer. In 2011, a study in Gastroenterology linked a similar drug to a 2.7 times increased risk of pancreatic cancer.